Skip header and navigation

Refine By

4650 records – page 1 of 465.

A 1-year evaluation of Syva MicroTrak Chlamydia enzyme immunoassay with selective confirmation by direct fluorescent-antibody assay in a high-volume laboratory.

https://arctichealth.org/en/permalink/ahliterature217461
Source
J Clin Microbiol. 1994 Sep;32(9):2208-11
Publication Type
Article
Date
Sep-1994
Author
E L Chan
K. Brandt
G B Horsman
Author Affiliation
Laboratory and Disease Control Services, Saskatchewan Health, Regina, Canada.
Source
J Clin Microbiol. 1994 Sep;32(9):2208-11
Date
Sep-1994
Language
English
Publication Type
Article
Keywords
Algorithms
Chlamydia Infections - diagnosis - epidemiology - microbiology
Chlamydia trachomatis - immunology - isolation & purification
Cost Control
Densitometry
Diagnostic Tests, Routine - economics
Evaluation Studies as Topic
Female
Fluorescent Antibody Technique - economics
Humans
Immunoenzyme Techniques - economics
Male
Predictive value of tests
Prevalence
Reagent kits, diagnostic
Saskatchewan - epidemiology
Seasons
Sensitivity and specificity
Urethritis - diagnosis - epidemiology - microbiology
Uterine Cervicitis - diagnosis - epidemiology - microbiology
Abstract
TThe Syva MicroTrak Chlamydia enzyme immunoassay (EIA; Syva Company, San Jose, Calif.) with cytospin and direct fluorescent-antibody assay (DFA) confirmation was evaluated on 43,630 urogenital specimens over a 1-year period in the Provincial Laboratory in Regina, Saskatchewan, Canada. This was a two-phase study intended to define a testing algorithm for Chlamydia trachomatis that would be both highly accurate and cost-effective in our high-volume (> 3,000 tests per month) laboratory. The prevalence of C. trachomatis infection in our population is moderate (8 to 9%). In phase 1, we tested 6,022 male and female urogenital specimens by EIA. All specimens with optical densities above the cutoff value and those within 30% below the cutoff value were retested by DFA. This was 648 specimens (10.8% of the total). A total of 100% (211 of 211) of the specimens with optical densities equal to or greater than 1.00 absorbance unit (AU) above the cutoff value, 98.2% (175 of 178) of the specimens with optical densities of between 0.500 and 0.999 AU above the cutoff value, and 83% (167 of 201) of the specimens with optical densities within 0.499 AU above the cutoff value were confirmed to be positive. A total of 12% (7 of 58) of the specimens with optical densities within 30% below the cutoff value were positive by DFA. In phase 2, we tested 37,608 specimens (32,495 from females; 5,113 from males) by EIA. Only those specimens with optical densities of between 0.499 AU above and 30% below the cutoff value required confirmation on the basis of data from phase 1 of the study. This was 4.5% of all specimens tested. This decrease in the proportion of specimens requiring confirmation provides a significant cost savings to the laboratory. The testing algorithm gives us a 1-day turnaround time to the final confirmed test results. The MicroTrak EIA performed very well in both phases of the study, with a sensitivity, specificity, positive predictive value, and negative predictive value of 96.1, 99.1, 90.3, and 99.7%, respectively, in phase 2. We suggest that for laboratories that use EIA for Chlamydia testing, a study such as this one will identify an appropriate optical density range for confirmatory testing for samples from that particular population.
Notes
Cites: Epidemiol Rev. 1983;5:96-1236357824
Cites: J Clin Microbiol. 1993 Jun;31(6):1646-78315010
Cites: Diagn Microbiol Infect Dis. 1992 Nov-Dec;15(8):663-81478048
Cites: J Clin Microbiol. 1990 Nov;28(11):2473-62254422
PubMed ID
7814548 View in PubMed
Less detail

A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults.

https://arctichealth.org/en/permalink/ahliterature56626
Source
Scand J Infect Dis. 2002;34(8):610-4
Publication Type
Article
Date
2002
Author
K. Levie
I. Gjorup
P. Skinhøj
M. Stoffel
Source
Scand J Infect Dis. 2002;34(8):610-4
Date
2002
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Belgium
Comparative Study
Denmark
Dose-Response Relationship, Drug
Female
Hepatitis B - prevention & control
Hepatitis B Antibodies - analysis
Hepatitis B Surface Antigens - analysis
Hepatitis B vaccines - administration & dosage
Humans
Immunity - physiology
Immunization - methods
Immunization Schedule
Male
Reference Values
Research Support, Non-U.S. Gov't
Sensitivity and specificity
Single-Blind Method
Vaccines, Synthetic - administration & dosage
Abstract
An open-label randomized study was undertaken to compare a 2-dose regimen (Months 0 and 6) of hepatitis B surface antigen (HBsAg) vaccine formulated with a novel adjuvant (HBsAg/AS04) with a standard 3-dose regimen (Months 0, 1 and 6) of licensed recombinant HBsAg vaccine in terms of immunogenicity and reactogenicity when administered to healthy subjects aged between 15 and 40 y. At 1 and 6 months after the full vaccination course there was a 100% seroprotection rate (anti-HBs > or = 10 mIU/ml) with the HBsAg/AS04 vaccine, compared with a 99% response rate with the licensed vaccine. The corresponding geometric mean titres were significantly higher for the novel vaccine compared to the standard vaccine: 15,468 and 2,745 mIU/ml at Months 7 and 12 vs. 6,274 and 1,883 mIU/ml, respectively. There was a higher prevalence of local symptoms with the adjuvant vaccine (90% of doses) than with the standard vaccine (48% of doses). However, these symptoms (pain, swelling and redness) were predominantly of mild-to-moderate intensity and resolved rapidly without treatment. A 2-dose regimen of the new HBsAg/AS04 adjuvant vaccine therefore compared favourably to the standard regimen in healthy young adults. It is anticipated that the simplified vaccination schedule may improve compliance and reduce costs.
PubMed ID
12238579 View in PubMed
Less detail

[3 cases of viral carriage detected during screening for HIV antibodies].

https://arctichealth.org/en/permalink/ahliterature226768
Source
Zh Mikrobiol Epidemiol Immunobiol. 1991 Mar;(3):16-8
Publication Type
Article
Date
Mar-1991
Author
E M Shelukhina
E V Chekunova
G R Matsevich
I A Okunev
S S Marennikova
M R Zak
Source
Zh Mikrobiol Epidemiol Immunobiol. 1991 Mar;(3):16-8
Date
Mar-1991
Language
Russian
Publication Type
Article
Keywords
Acquired Immunodeficiency Syndrome - epidemiology - immunology - prevention & control
Blood Donors
Carrier State - epidemiology - immunology - prevention & control
Enzyme-Linked Immunosorbent Assay
HIV Antibodies - blood
HIV Seropositivity - epidemiology - immunology
HIV-1 - immunology
Humans
Immunoblotting
Lithuania - epidemiology
Mass Screening - methods
Moscow - epidemiology
Risk factors
Abstract
The results of screening more than 23,000 serum samples from persons belonging to risk groups, as well as those not belonging to such groups, in Moscow, Vilnius and Klaipeda are presented. Screening was carried out with the use of an assay system manufactured by the Scientific and Industrial Amalgamation "Antigen" (USSR). In this screening 3 HIV carriers were detected; of these, 2 were foreign students from two African countries.
PubMed ID
1872091 View in PubMed
Less detail

The 3 mm skin prick test (SPT) threshold criterion is not reliable for Tyrophagus putrescentiae: the re-evaluation of SPT criterion to dust mites.

https://arctichealth.org/en/permalink/ahliterature71486
Source
Allergy. 2002 Dec;57(12):1187-90
Publication Type
Article
Date
Dec-2002
Author
B. Kanceljak-Macan
J. Macan
D. Plavec
T. Klepac
S. Milkovic-Kraus
Author Affiliation
Institute for Medical Research and Occupational Health, Zagreb, Croatia.
Source
Allergy. 2002 Dec;57(12):1187-90
Date
Dec-2002
Language
English
Publication Type
Article
Keywords
Adult
Antibody Specificity - immunology
Comparative Study
Croatia
Cross Reactions - immunology
Dermatophagoides farinae - immunology
Dermatophagoides pteronyssinus - immunology
Female
Humans
Immunoglobulin E - blood - immunology
Male
Middle Aged
Proteins - immunology
Pyroglyphidae - immunology
Regression Analysis
Reproducibility of Results
Sensitivity and specificity
Skin Tests - standards
Urban health
Abstract
BACKGROUND: The mean wheal diameter >/= 3 mm is the usual criterion for positive skin prick test (SPT) reaction to dust mites. The study assessed the accuracy of this SPT criterion with respect to specific IgE values of above 0.35 kUA/l (+ sIgE). METHODS: Specific IgE (ImmunoCAP, Pharmacia AB Diagnostics, Uppsala, Sweden) and standard SPT to Dermatophagoides pteronyssinus (DP) and farinae (DF), Lepidoglyphus destructor (LD) and Tyrophagus putrescentiae (TP) (ALK, Hørsholm, Denmark) were performed in a random sample of 457 subjects, of whom 273 men (mean age 35.3 +/- 11.0 years) and 184 women (mean age 37.9 +/- 9.5 years). Statistical analysis was performed using the chi-square test, regression analysis and discriminant analysis. RESULTS: When the mean wheal diameter of >/= 3 mm was considered positive (+ SPT), the correlation between + SPT and + sIgE was 0.47 for DP (P
PubMed ID
12464048 View in PubMed
Less detail

4th Scandinavian Symposium on Radiolabeled Monoclonal Antibodies in Diagnosis and Therapy of Cancer. Lillehammer, Norway, January 15-17, 1995.

https://arctichealth.org/en/permalink/ahliterature22942
Source
Acta Oncol. 1996;35(3):257-390
Publication Type
Conference/Meeting Material
Article
Date
1996

5-oxo-ETE induces pulmonary eosinophilia in an integrin-dependent manner in Brown Norway rats.

https://arctichealth.org/en/permalink/ahliterature10761
Source
J Clin Invest. 1998 Dec 15;102(12):2165-72
Publication Type
Article
Date
Dec-15-1998
Author
P. Stamatiou
Q. Hamid
R. Taha
W. Yu
T B Issekutz
J. Rokach
S P Khanapure
W S Powell
Author Affiliation
Meakins-Christie Laboratories, Department of Medicine, McGill University, Montreal, Quebec, Canada, H2X 2P2.
Source
J Clin Invest. 1998 Dec 15;102(12):2165-72
Date
Dec-15-1998
Language
English
Publication Type
Article
Keywords
Animals
Antibodies, Monoclonal - pharmacology
Antigens, CD - metabolism
Arachidonic Acids - administration & dosage - pharmacology
Chemotactic Factors - pharmacology
Immunohistochemistry
Integrin alpha4
Integrins - metabolism
Intubation, Intratracheal - methods
Leukotrienes - pharmacology
Lung - cytology - drug effects
Macrophage-1 Antigen - metabolism
Male
Platelet Activating Factor - pharmacology
Pulmonary Eosinophilia - chemically induced
Rats
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, U.S. Gov't, P.H.S.
Time Factors
Abstract
We have shown previously that the 5-lipoxygenase product 5-oxo-6,8, 11,14-eicosatetraenoic acid (5-oxo-ETE) is a highly potent eosinophil chemoattractant in vitro. To determine whether this substance can induce pulmonary eosinophil infiltration in vivo, it was administered to Brown Norway rats by tracheal insufflation. Eosinophils were then counted in lung sections that had been immunostained with an antibody to eosinophil major basic protein. 5-Oxo-ETE induced a dramatic increase in the numbers of eosinophils (ED50, 2.5 microg) around the walls of the airways, which reached maximal levels (five times control levels) between 15 and 24 h after administration, and then declined. LTB4 also induced pulmonary eosinophil infiltration with a similar ED50 but appeared to be somewhat less effective. In contrast, LTD4 and LTE4 were inactive. 5-Oxo-ETE-induced eosinophilia was unaffected by the LTB4 and PAF antagonists LY255283 and WEB 2170, respectively. However, it was inhibited by approximately 75% by monoclonal antibodies to CD49d (VLA-4) or CD11a (LFA-1) but was not significantly affected by an antibody to CD11b (Mac-1). In conclusion, 5-oxo-ETE induces pulmonary eosinophilia in Brown Norway rats, raising the possibility that it may be a physiological mediator of inflammation in asthma.
PubMed ID
9854052 View in PubMed
Less detail

7-Alkoxyquinoline O-dealkylation by microsomes from human liver and placenta.

https://arctichealth.org/en/permalink/ahliterature64902
Source
Br J Clin Pharmacol. 1992 Nov;34(5):415-20
Publication Type
Article
Date
Nov-1992
Author
J. Hakkola
J. Mäenpää
R T Mayer
S S Park
H V Gelboin
O. Pelkonen
Author Affiliation
Department of Pharmacology and Toxicology, University of Oulu, Finland.
Source
Br J Clin Pharmacol. 1992 Nov;34(5):415-20
Date
Nov-1992
Language
English
Publication Type
Article
Keywords
Animals
Antibodies, Monoclonal - diagnostic use
Benzyl Compounds - metabolism
Cytochrome P-450 Enzyme System - antagonists & inhibitors - metabolism
Dealkylation
Female
Humans
In Vitro
Male
Mice
Mice, Inbred Strains
Microsomes - enzymology - metabolism
Microsomes, Liver - enzymology - metabolism
Placenta - enzymology - metabolism
Pregnancy
Quinolines - metabolism
Rats
Rats, Wistar
Research Support, Non-U.S. Gov't
Smoking - metabolism
Abstract
1. The O-dealkylation of seven 7-alkoxyquinoline derivatives by human hepatic and placental microsomes and the effect of maternal cigarette smoking on placental 7-alkoxyquinoline metabolism was studied. 2. None of several monoclonal antibodies to isoenzymes of cytochrome P450 had a clear effect on metabolism of the compounds by liver microsomes. 3. Maternal cigarette smoking induced the O-dealkylation of all of the 7-alkoxyquinoline derivatives, being greatest for 7-butoxy- and 7-benzyloxyquinoline. 4. Placental 7-alkoxyquinoline metabolism induced by smoking was partially inhibited by the monoclonal antibody 1-7-1 raised against 3-methylcholanthrene-induced rat liver P450. 5. None of the 7-alkoxyquinoline O-dealkylations could be assigned specifically to any known P450 isoenzyme in human liver or placenta.
PubMed ID
1467136 View in PubMed
Less detail

[10 years of testing of the HER2 status in breast cancer in Russia].

https://arctichealth.org/en/permalink/ahliterature116989
Source
Arkh Patol. 2012 Sep-Oct;74(5):3-6
Publication Type
Article

The 13-valent pneumococcal conjugate vaccine for invasive pneumococcal disease in Alaska native children: results of a clinical trial.

https://arctichealth.org/en/permalink/ahliterature120452
Source
Pediatr Infect Dis J. 2013 Mar;32(3):257-63
Publication Type
Article
Date
Mar-2013

A 15-year surveillance study of antibodies to herpes simplex virus types 1 and 2 in a cohort of young girls.

https://arctichealth.org/en/permalink/ahliterature49320
Source
J Infect. 1992 Sep;25(2):147-54
Publication Type
Article
Date
Sep-1992
Author
B. Christenson
M. Böttiger
A. Svensson
S. Jeansson
Author Affiliation
Department of Environmental Health and Infectious Diseases Control, Karolinska Hospital, Stockholm, Sweden.
Source
J Infect. 1992 Sep;25(2):147-54
Date
Sep-1992
Language
English
Publication Type
Article
Keywords
Adolescent
Antibodies, Viral - blood
Cohort Studies
Female
Herpes Simplex - epidemiology - microbiology
Humans
Simplexvirus - immunology
Species Specificity
Sweden - epidemiology
Time Factors
Abstract
A cohort of 839 young girls at the ages of 14 and 15 years was screened for total antibodies to herpes simplex virus (HSV) and, if positive, for specific antibodies to HSV-2, by means of a sensitive, enzyme-linked immunosorbent assay (ELISA). The cohort was followed from 1972-1987. Blood samples were obtained on six occasions during these 16 years. In total, 2270 blood samples were taken. The number of sero-converting girls was studied in relation to calendar time. Two methods were constructed for the statistical analyses. The first of these gave an estimate of the sero-prevalence at different points in time. This analysis showed that the sero-prevalence which was 23% against HSV-1 in 1972 had increased to 36% in 1976. At the end of the study in 1987, 50% of the cohort had sero-converted against HSV-1. The proportion of girls who had sero-converted against HSV-2 was 0.4% in the 14-15-year-olds and had reached 22% by the end of the study. The second statistical method used all the available information implicit in the observations so as to obtain a maximum-likelihood (ML) estimate of the prevalence. The ML estimates were slightly more precise, but the two estimates did not differ significantly. The observations were further analysed by the Mantel-Haenszel test in order to see if there was any dependence between positivity to HSV-1 and HSV-2 respectively but none was found.
PubMed ID
1331244 View in PubMed
Less detail

4650 records – page 1 of 465.